Neurosurgery · 2018
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Radiosurgery and Radiation Therapy in the Management of Patients With Vestibular Schwannomas.
СтатьяКлинические рекомендацииПоддержка исследования: вне правительства СШАСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Germano Isabelle M, Sheehan Jason, Parish Johnathan, Atkins Tyler, Asher Anthony, Hadjipanayis Constantinos G, Burri Stuart H, Green Sheryl, Olson Jeffrey J
Аннотация
QUESTION: What are the indications for stereotactic radiosurgery (SRS) treatment vs observation for patients with intracanalicular vestibular schwannomas without evidence of radiographic progression?
RECOMMENDATION: Level 3: If tinnitus is not observed at presentation, it is recommended that intracanalicular vestibular schwannomas and small tumors (<2 cm) without tinnitus be observed as observation does not have a negative impact on tumor growth or hearing preservation compared to treatment.
QUESTION: Is there a difference in outcome based on radiosurgery equipment used: Gamma Knife (Elekta, Stockholm, Sweden) vs linear accelerator-based radiosurgery vs proton beam?
RECOMMENDATION: There are no studies that compare 2 or all 3 modalities. Thus, recommendations on outcome based on modality cannot be made.
QUESTION: Is there a difference in outcome based on the dose delivered?
RECOMMENDATION: Level 3: As there is no difference in radiographic control using different doses, it is recommended that for single fraction SRS doses, <13 Gy be used to facilitate hearing preservation and minimize new onset or worsening of preexisting cranial nerve deficits.
QUESTION: Is there a difference in outcome based on the number of fractions?
RECOMMENDATION: As there is no difference in radiographic control and clinical outcome using single or multiple fractions, no recommendations can be given.
QUESTION: What is the best time sequence for follow-up images after SRS?
RECOMMENDATION: Level 3: Follow-up imaging should be obtained at intervals after SRS based on clinical indications, a patient's personal circumstances, or institutional protocols. Long-term follow-up with serial magnetic resonance imagings to evaluate for recurrence is recommended. No recommendations can be given regarding the interval of these studies.
QUESTION: Is there a role for retreatment?
RECOMMENDATION: Level 3: When there has been progression of tumor after SRS, SRS can be safely and effectively performed as a retreatment.
QUESTION: What is the risk of radiation-induced malignant transformation of vestibular schwannomas treated with SRS?
RECOMMENDATION: Level 3: Patients should be informed that there is minimal risk of malignant transformation of vestibular schwannomas after SRS.
QUESTION: What are the indications for SRS in patients with neurofibromatosis type 2?
RECOMMENDATION: Level 3: Radiosurgery is a treatment option for patients with neurofibromatosis type 2 whose vestibular schwannomas are enlarging and/or causing hearing loss. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-management-patients-vestibular-schwannoma/chapter_7.
RECOMMENDATION: Level 3: If tinnitus is not observed at presentation, it is recommended that intracanalicular vestibular schwannomas and small tumors (<2 cm) without tinnitus be observed as observation does not have a negative impact on tumor growth or hearing preservation compared to treatment.
QUESTION: Is there a difference in outcome based on radiosurgery equipment used: Gamma Knife (Elekta, Stockholm, Sweden) vs linear accelerator-based radiosurgery vs proton beam?
RECOMMENDATION: There are no studies that compare 2 or all 3 modalities. Thus, recommendations on outcome based on modality cannot be made.
QUESTION: Is there a difference in outcome based on the dose delivered?
RECOMMENDATION: Level 3: As there is no difference in radiographic control using different doses, it is recommended that for single fraction SRS doses, <13 Gy be used to facilitate hearing preservation and minimize new onset or worsening of preexisting cranial nerve deficits.
QUESTION: Is there a difference in outcome based on the number of fractions?
RECOMMENDATION: As there is no difference in radiographic control and clinical outcome using single or multiple fractions, no recommendations can be given.
QUESTION: What is the best time sequence for follow-up images after SRS?
RECOMMENDATION: Level 3: Follow-up imaging should be obtained at intervals after SRS based on clinical indications, a patient's personal circumstances, or institutional protocols. Long-term follow-up with serial magnetic resonance imagings to evaluate for recurrence is recommended. No recommendations can be given regarding the interval of these studies.
QUESTION: Is there a role for retreatment?
RECOMMENDATION: Level 3: When there has been progression of tumor after SRS, SRS can be safely and effectively performed as a retreatment.
QUESTION: What is the risk of radiation-induced malignant transformation of vestibular schwannomas treated with SRS?
RECOMMENDATION: Level 3: Patients should be informed that there is minimal risk of malignant transformation of vestibular schwannomas after SRS.
QUESTION: What are the indications for SRS in patients with neurofibromatosis type 2?
RECOMMENDATION: Level 3: Radiosurgery is a treatment option for patients with neurofibromatosis type 2 whose vestibular schwannomas are enlarging and/or causing hearing loss. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-management-patients-vestibular-schwannoma/chapter_7.